| Literature DB >> 35566299 |
Jerry O Adeyemi1, Lukman O Olasunkanmi2,3, Adewale O Fadaka4, Nicole R S Sibuyi4, Adebola O Oyedeji1, Damian C Onwudiwe5.
Abstract
In this study, chlorophenyltin(IV) [(C6H5)(Cl)Sn(L)2] and diphenyltin(IV) [(C6H5)2Sn(L)2] of N-methyl-N-hydroxyethyldithiocarbamate were prepared and characterized using various spectroscopic methods (FTIR, 1H, 13C, and 119Sn NMR) and elemental analysis. The FTIR and NMR spectral data, used to establish the structure of the compounds, showed the formation of the complexes via coordination to the two sulfur atoms from the dithiocarbamate ligand and the respective phenyltin(IV) derivatives. This coordination mode was further explored by DFT calculations, which showed that the bonding around the Sn center in [(C6H5)2Sn(L)2] was more asymmetric compared to the bonding around [(C6H5)(Cl)Sn(L)2]. However, the Sn-S bonds in [(C6H5)(Cl)Sn(L)2] were found to be more covalent than those in [(C6H5)2Sn(L)2]. Furthermore, the charge density of the frontier orbitals showed that the Sn atom in the complexes is relatively electrophilic and the Sn atom in [(C6H5)2Sn(L)2] has a lower atomic dipole moment than that of [(C6H5)(Cl)Sn(L)2]. The cytotoxicity and anti-inflammatory study revealed that [(C6H5)2Sn(L)2], with the higher number of phenyl substituents, has a higher potency than [(C6H5)(Cl)Sn(L)2]. The bio-efficacy study of these complexes as cytotoxic and anti-inflammatory agents showed that the complexes possessed moderate to high activity in comparison to the camptothecin and diclofenac in each case. Nevertheless, the diphenyltin(IV) derivative [(C6H5)2Sn(L)2] was found to possess a better activity than its counterpart due to the number of phenyl rings attached to the Sn center.Entities:
Keywords: DFT calculation; anti-inflammatory assay; cytotoxicity; dithiocarbamate; organotin complex
Mesh:
Substances:
Year: 2022 PMID: 35566299 PMCID: PMC9105561 DOI: 10.3390/molecules27092947
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Scheme 1Synthetic scheme of the phenyltin(IV) N-methyl-N-hydroxyethyldithiocarbamate complexes.
Figure 1Optimized ground state equilibrium structures of (a) syn-syn conformation of [(C (b) anti-anti conformation of [(C (c) syn-syn conformation of [(C6H5)2Sn(L)2], and (d) anti-anti conformation of [(C6H5)2Sn(L)2], obtained at M06/cc-TVPZ//LANL2DZ level.
Selected second-order perturbation energy values.
| [(C6H5)(Cl)Sn(L)2] | [(C6H5)2Sn(L)2] | |||
|---|---|---|---|---|
| E(2) (kJ/mol) | E(2) (kJ/mol) | |||
| Donor → Acceptor Interactions | Syn-Syn | Anti-Anti | Syn-Syn | Anti-Anti |
| BD(1) S2-C6 → LP*Sn(1) | 42.43 | 41.97 | 41.09 | 40.67 |
| BD(1) S3-C6 → LP*Sn(1) | 40.92 | 40.96 | 25.94 | 25.52 |
| BD(1) S4-C20 → LP*Sn(1) | 40.58 | 41.59 | 23.35 | 23.68 |
| BD(1) S5-C20 → LP*Sn(1) | 42.13 | 41.55 | 39.96 | 39.96 |
| LP(3)S2 → LP*(2)Sn1 | 202.97 | 256.10 | 586.85 | 285.77 |
Figure 2FMO isosurfaces of the complexes of [(C (a) HOMO−1, (b) HOMO, (c) LUMO, (d) LUMO+1, and [(C6H5)2Sn(L)2] (e) HOMO−1, (f) HOMO, (g) LUMO, and (h) LUMO+1 (Iso-value = 0.020000).
Atomic orbital compositions of the HOMO, LUMO, HOMO−1, and LUMO+1 of [(C and [(C6H5)2Sn(L)2] (only contributions greater than or equal to 1.0 are recorded).
| Composition (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Atom | [(C6H5)(Cl)Sn(L)2] | [(C6H5)2Sn(L)2] | ||||||
| HOMO | LUMO | HOMO−1 | LUMO+1 | HOMO | LUMO | HOMO−1 | LUMO+1 | |
| Sn1 | - | 39.26 | - | 3.53 | - | 3.10 | - | 1.51 |
| S2 | 10.96 | 7.43 | 8.80 | 5.80 | 10.82 | 6.81 | 4.91 | 5.31 |
| S3 | 27.07 | 7.27 | 19.70 | 5.50 | 18.23 | 11.21 | 50.60 | 7.59 |
| S4 | 8.36 | 7.48 | 8.48 | 10.54 | 44.10 | 9.28 | 28.66 | 11.56 |
| S5 | 20.89 | 7.31 | 24.37 | 9.98 | 14.01 | 4.55 | 2.25 | 7.00 |
| C6 | - | 1.11 | - | 15.05 | - | 24.40 | 1.13 | 17.38 |
| N7 | 1.24 | - | - | 4.76 | - | 7.44 | - | 5.05 |
| C20 | - | - | - | 27.58 | - | 18.46 | - | 23.23 |
| N21 | 1.08 | - | - | 8.43 | - | 5.60 | - | 6.51 |
| Cl34 | 17.12 | 11.90 | - | - | - | - | - | - |
| C34 | - | - | - | - | 1.13 | - | 2.62 | - |
| C35 | 3.79 | 7.53 | 2.11 | - | 1.12 | - | - | - |
| C36 | 1.20 | 1.09 | 6.15 | - | - | - | - | - |
| C37 | - | 1.09 | 8.03 | - | - | - | - | - |
| C38 | - | - | 9.41 | - | - | - | - | - |
| C40 | 1.12 | - | 7.76 | - | - | - | - | - |
| C42 | 2.77 | - | - | - | - | - | - | 2.00 |
| C45 | - | - | - | - | 1.21 | - | 2.70 | - |
| C46 | - | - | - | - | 1.09 | - | - | - |
| C52 | - | - | - | - | 1.40 | - | - | - |
The IC of the mono- and diphenyltin(IV) N-methyl-N-hydroxyethyldithiocarbamate complexes and camptothecin.
| Samples | KMST-6 (µM) | Caco-2 (µM) | PC-3 (µM) |
|---|---|---|---|
|
| >100 | >100 | >100 |
|
| 11.81 ± 0.15 | 4.937 ± 0.12 | 1.630 ± 0.10 |
| Camptothecin | 59.91 ± 0.21 | >100 | 24.41 ± 0.11 |
Figure 3Cytotoxicity of the phenyltin(IV) complexes: [(C6H5)2Sn(L)2] and [(C on cancer and non-cancer cells. Cell viability (%) was assessed by means of MTT assay after 24 h.
Figure 4Effect of the phenyltin(IV) complexes [(C6H5)2Sn(L)2] and [(C] and Camptothecin on cellular morphology after 24 h treatment with 100 µM.